Zoledronic Acid in Vivo Increases in Vitro Proliferation of Rat Mesenchymal Stromal Cells

Overview

Journal Acta Orthop

Specialty Orthopedics

Date 2016 May 20

PMID 27196705

Citations 5

Authors

Terhi J Heino

Jessica J Alm

Heikki J Halkosaari

Ville-Valtteri Valimaki

Affiliations

Soon will be listed here.

Abstract

Background and purpose - Bisphosphonates are widely used in the treatment of bone loss, but they might also have positive effects on osteoblastic cells and bone formation. We evaluated the effect of in vivo zoledronic acid (ZA) treatment and possible concomitant effects of ZA and fracture on the ex vivo osteogenic capacity of rat mesenchymal stromal cells (MSCs). Methods - A closed femoral fracture model was used in adult female rats and ZA was administered as a single bolus or as weekly doses up to 8 weeks. Bone marrow MSCs were isolated and cultured for in vitro analyses. Fracture healing was evaluated by radiography, micro-computed tomography (μCT), and histology. Results - Both bolus and weekly ZA increased fracture-site bone mineral content and volume. MSCs from weekly ZA-treated animals showed increased ex vivo proliferative capacity, while no substantial effect on osteoblastic differentiation was observed. Fracture itself did not have any substantial effect on cell proliferation or differentiation at 8 weeks. Serum biochemical markers showed higher levels of bone formation in animals with fracture than in intact animals, while no difference in bone resorption was observed. Interestingly, ex vivo osteoblastic differentiation of MSCs was found to correlate with in vivo serum bone markers. Interpretation - Our data show that in vivo zoledronic acid treatment can influence ex vivo proliferation of MSCs, indicating that bisphosphonates can have sustainable effects on cells of the osteoblastic lineage. Further research is needed to investigate the mechanisms.

Citing Articles

The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis.

Gao Y, Liu X, Gu Y, Song D, Ding M, Liao L Front Endocrinol (Lausanne). 2021; 12:688269.

PMID: 34526966 PMC: 8435630. DOI: 10.3389/fendo.2021.688269.

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche.

Solimando A, Vacca A, Ribatti D J Oncol. 2020; 2020:6820241.

PMID: 32508920 PMC: 7251466. DOI: 10.1155/2020/6820241.

Zoledronic acid prevents disuse osteopenia and augments gene expression of osteoclastic differentiation markers in mice.

Vegger J, Bruel A, Thomsen J J Musculoskelet Neuronal Interact. 2018; 18(2):165-175.

PMID: 29855438 PMC: 6016491.

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?.

Xu S, de Veirman K, De Becker A, Vanderkerken K, Van Riet I Leukemia. 2018; 32(7):1500-1514.

PMID: 29535427 PMC: 6035148. DOI: 10.1038/s41375-018-0061-9.

Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients.

Dalle Carbonare L, Mottes M, Malerba G, Mori A, Zaninotto M, Plebani M Int J Mol Sci. 2017; 18(6).

PMID: 28608802 PMC: 5486083. DOI: 10.3390/ijms18061261.

References

Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H . Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res. 2000; 15(10):2042-51. DOI: 10.1359/jbmr.2000.15.10.2042. View

Bellido T, Plotkin L . Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2010; 49(1):50-5. PMC: 2994972. DOI: 10.1016/j.bone.2010.08.008. View

Im G, Qureshi S, Kenney J, Rubash H, Shanbhag A . Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004; 25(18):4105-15. DOI: 10.1016/j.biomaterials.2003.11.024. View

Bravenboer N, Papapoulos S, Holzmann P, Hamdy N, Netelenbos J, Lips P . Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int. 2000; 9(6):489-93. DOI: 10.1007/s001980050175. View

Alm J, Heino T, Hentunen T, Vaananen H, Aro H . Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods. 2012; 18(9):658-66. DOI: 10.1089/ten.TEC.2011.0675. View

Storm T, Steiniche T, Thamsborg G, Melsen F . Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993; 8(2):199-208. DOI: 10.1002/jbmr.5650080211. View

Bonnarens F, Einhorn T . Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984; 2(1):97-101. DOI: 10.1002/jor.1100020115. View

Rogers M . New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-58. DOI: 10.2174/1381612033453640. View

Maruotti N, Corrado A, Neve A, Cantatore F . Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012; 68(7):1013-8. DOI: 10.1007/s00228-012-1216-7. View

10.

Gourion-Arsiquaud S, Allen M, Burr D, Vashishth D, Tang S, Boskey A . Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. 2009; 46(3):666-72. PMC: 2823979. DOI: 10.1016/j.bone.2009.11.011. View

11.

Fleisch H . Development of bisphosphonates. Breast Cancer Res. 2002; 4(1):30-4. PMC: 138713. DOI: 10.1186/bcr414. View

12.

Zhou S, LeBoff M, Glowacki J . Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology. 2009; 151(1):14-22. PMC: 2803155. DOI: 10.1210/en.2009-0969. View

13.

Szulc P . The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem. 2012; 45(12):907-19. DOI: 10.1016/j.clinbiochem.2012.01.022. View

14.

McDonald M, Dulai S, Godfrey C, Amanat N, Sztynda T, Little D . Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008; 43(4):653-62. DOI: 10.1016/j.bone.2008.05.019. View

15.

Valimaki V, Moritz N, Yrjans J, Vuorio E, Aro H . Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone. 2005; 38(3):432-43. DOI: 10.1016/j.bone.2005.09.016. View

16.

Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimatsu H . Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res. 1999; 14(6):969-79. DOI: 10.1359/jbmr.1999.14.6.969. View

17.

Boyce R, Paddock C, Gleason J, Sletsema W, Eriksen E . The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res. 1995; 10(2):211-21. DOI: 10.1002/jbmr.5650100207. View

18.

Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P . Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100(6):1475-80. PMC: 508326. DOI: 10.1172/JCI119668. View

19.

Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G . Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 1998; 22(5):455-61. DOI: 10.1016/s8756-3282(98)00033-7. View

20.

Reinholz G, Getz B, Pederson L, Sanders E, Subramaniam M, Ingle J . Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000; 60(21):6001-7. View